RJR-2403 (oxalate)(220662-95-3)
- Name: RJR-2403 (oxalate)
- Synonyms:RJR-2403 oxalate||Rivanicline oxalate|RJR 2403 oxalate;Rivanicline oxalate;CS-0531;RJR-2403 oxalate;
- Molecular Formula:C10H14N2.C2H2O4
- Molecular Weight:252.26644
- CAS Registry Number:220662-95-3
- EINECS:
- Melting Point:
- Water Solubility:
CAS No.220662-95-3 RJR-2403 (oxalate)
Assay:99.0% Appearance:liquid Package:Grams, Kilograms Storage:Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials. Transportation:According to customer request Application:For R&D and commerical use
Min. Order:100Gram
Supplier:Chemlyte Solutions [
China (Mainland)] CAS No.220662-95-3 RJR-2403 (oxalate)
Assay:99% Package:box or opp package Storage:cool drum Transportation:air or sea Application:RJR-2403 (oxalate)
Min. Order:1Milligram
Supplier:weifang yangxu group co.,ltd [
China (Mainland)] CAS No.220662-95-3 RJR-2403 oxalate
Assay:97% Appearance:Powder or liquid Package:According to customer Storage:Store in a tightly closed container, in a cool and dry place. Transportation:Fedex,DHL,TNT,BY SEA and BY AIR Application:Medicinal ChemistryBiomedicinePharmaceutical intermediatesChemistry experimentBiological experimentsChemical reagentFor R&D use only.
Min. Order:10Milligram
Supplier:Amadis Chemical Co., Ltd. [
China (Mainland)] CAS No.220662-95-3 RJR-2403 oxalate
Assay:>98% Package:inquiry Transportation:inquiry Application:A neuronal nicotinic receptor agonist, showing high selectivity for the 伪4尾2 subtype (Ki values are 26 and 36000 nM for 伪4尾2 and 伪7 receptors respectively). Active in vivo.
Min. Order:0
Supplier:BOC Sciences [
United States] CAS No.220662-95-3 RJR-2403 oxalate
Assay:98% Package:According to the demand of customer Storage:Sealed, dry, microtherm , avoid light and smell. Transportation:by air or by sea Application:Organic synthesis
Min. Order:0
Supplier:Henan Allgreen Chemical Co.,Ltd [
China (Mainland)]
Other Product
- 862812-98-4/CAY10576
- 153653-31-7/Dofequidar (S)-isomer
- 959986-66-4/4-iodo-1-Methyl-1H-pyrazole-5-carbaldehyde
- 153653-33-9/Dofequidar (R)-isomer
- 1190378-57-4/N-[3-[[5-Cyclopropyl-2-[[3-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]cyclobutanecarboxamide
- 939375-07-2/RO-5006036
- 1220171-17-4/CCR1 antagonist 5
- 104846-63-1/tert-butyl((E)-3-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-diMethylhept-3-en-2-yl)-7a-Methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-Methylenecyclohexyloxy)diMethylsilane
- 1184940-47-3/(alphaR)-3,5-Difluoro-alpha-hydroxybenzeneacetic acid 2-(2-ethyl-4-hydroxy-3-methylbenzoyl)hydrazide
- 761436-81-1/ALK inhibitor 1
- 895158-95-9/SC 144
- 865479-71-6/5-R-Rivaroxaban
- 565434-85-7/CBP-501
- 620616-08-2/Benzeneethanol, β-aMino-3-chloro-, hydrochloride (1:1), (βS)-
- 1229224-94-5/(αR)-α-Methyl-N-[3-[3-(trifluoroMethyl)phenyl)propyl]-1-napthaleneMethanaMine-N-oxide
- 496868-77-0/(2E)-3-(4'-Hydroxy-3'-tricyclo[3.3.1.13,7]dec-1-yl[1,1'-biphenyl]-4-yl)-2-propenoic acid
- 554435-83-5/Exjade Fe3+ chelate
- 1204416-97-6/TMC-647055
- 159878-04-3/[3S-(3S,4aS,8aS,2’R,3’R)]-2-[3’-N-CBz-amino-2’-hydroxy-4’-(phenyl)thio]butyldecahydroisoquinoline-3-N-t-butylcarboxamide
- 220662-95-3/RJR-2403 (oxalate)
- 864668-87-1/ENMD-119
- 1011557-82-6/Tenovin-6
- 557766-14-0/Benzo[3,4]-18-norandrosta-3,5-diene-3(2'H)-carboxylic acid, 3',4',5',6'-tetrahydro-17-(hydroxyimino)-4',4',9,14-tetramethyl-, methyl ester, (3β,4β,8α,9β,10α,13α,14β)- (9CI)
- 1233145-49-7/1-Piperidineacetamide, 4-[3-methoxy-4-[[7-(2-methoxyphenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]-
- 869811-23-4/FLUORAPACIN
- 328232-95-7/Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[1-(2-fluorophenyl)-1H-pyrazol-3-yl]-1'-oxo-, trans-
- 827034-92-4/D-erythro-Pentonic acid, 5-[[(1S)-2-[4-(2-butyn-1-yloxy)phenyl]-1-carboxyethyl]aMino]-3-C-carboxy-2,4,5-trideoxy-5-C-oxo-4-[(1E)-9-oxo-1-hexadecen-1-yl]-
- 1001667-23-7/ACH 0141625
- 863971-19-1/SGD 1269
- 1202400-18-7/CCR1 antagonist 2